Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Adaptimmune Therapeutics plc is a biopharmaceutical company specializing in engineered autologous T-cell therapies targeting solid tumor cancers. Its core products, including TECELRA and lete-cel, focus on treating synovial sarcoma and myxoid liposarcoma by modifying patients’ T-cells to recognize cancer-specific antigens. The company leverages proprietary T-cell receptor (TCR) and TRuC platforms, serving oncology patients through personalized immunotherapies with a commercial and clinical-stage business model.
This description was generated via AI from an annual report. Updated about 1 year ago.